← SynDRA
IRBESARTAN
SynDRA canonical compound SYN0008355 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | AGTR1 |
|---|
| Mechanism of action | Angiotensin receptor antagonist |
|---|
| Indication | diabetic nephropathy | hypertension |
|---|
| Disease area | cardiology | nephrology |
|---|
All known targets
- AGTR1
- SLC10A1
- Agtr1
- Agtr1b
- Agtr2
- EDNRA
- JUN
Mechanisms of action (all sources)
- Angiotensin receptor antagonist
- AGTR1 ANTAGONIST
- Type-1 angiotensin II receptor antagonist
- SLC10A1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- LTB4R2
- PPARG
- TBXA2R
- PDE3A
- MBD4
- MAOA
- MAPK1
- MAPK14
- MAPK3
- MC3R
- LMNA
- MC4R
- MC5R
- MLNR
- MMP1
- MMP9
- MPG
- LTB4R
- LCK
- NEIL1
- HTR1A
- GPR35
- HDAC6
- HMGCR
- HRH1
- HRH2
- HRH3
- HTR2A
- KCNH2
- HTR2B
- HTR2C
- HTR3A
- HTR5A
- HTR6
- HTR7
- MUTYH
- NPY1R
- NEIL2
- SLC6A3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP3A4
- CP3A7
- KCMB1
- KCMB2
Drug classes
- Angiotensin 2 Receptor Antagonists
- Angiotensin 2 Receptor Blocker
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
- Cardiovascular Agents
ATC classes
- C09C · ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
- ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Cross-references
Synonyms
- AVALIDE
- AVAPRO
- Avapro
- IRBESARTAN AND HYDROCHLOROTHIAZIDE
- aprovel
- irbesartan hydrochloride
- karvea
- ifirmasta
- irbesartan HCl
- Irbesartan bms
- Irbesartan teva
- Irbesartan zentiva
- Sarbevel
- BMS-186295
- NSC-758696
- SR-47436
- Aprovel
- Ifirmasta
- Irbesartan component of avalide
- Irbesartan component of coaprovel
- Irbesartan component of ibersartan/hydrochlorothiazide ibersartan
- Irbesartan component of ibersartan/hydrochlorothiazide teva ibersartan
- Irbesartan component of ibersartan/hydrochlorothiazide zentiva ibersartan
- Irbesartan component of ifirmacombi
- Irbesartan zentiva (previously irbesartan winthrop)
- Karvea
- Sabervel
- SR 47436
- BMS 186295
- Irbesartan [USAN:INN]
- UNII-J0E2756Z7N
- CHEMBL1513
- CHEBI:5959
- C25H28N6O
- YOSHYTLCDANDAN-UHFFFAOYSA-N
- J0E2756Z7N
- NCGC00095122-01
Reported adverse events
- Hypotension
- Urticaria
- Dizziness
- Fatigue
- Hypersensitivity
- Nausea
- Dyspepsia
- Intestinal angioedema
- Influenza
- Stevens-Johnson syndrome
- Tachycardia
- Anaphylactic reaction
Look up IRBESARTAN in the interactive SynDRA portal →